Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2024Annals of HematologyOpen Access

A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSylvain ChoquetCMClarisse MarchalFDFloriane Deygas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Choquet et al. (2024) studied this question.

synapsesocial.com/papers/68e613c8b6db6435875a6c15https://doi.org/10.1007/s00277-024-05859-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia2024
  2. 2Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study2024 · 9 citations
  3. 3Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  4. 45PSQ-104 Real-world evidence: is ibrutinib as safe as evidence tells?2024 · 1 citations
  5. 56ER-037 Pharmaco-utilisation of ibrutinib in CLL: a single centre study2024 · 1 citations